Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NQO1 | P15559 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800850 | 1.00 | CYP2C9 (0.55) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL10761190 | 0.95 | CYP2C9 (0.51) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL9260651 | 0.95 | CYP2C9 (0.51) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL17616203 | 0.95 | CYP2C9 (0.51) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL10761184 | 0.95 | CYP2C9 (0.51) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL17614872 | 0.95 | CYP2C9 (0.51) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL9260645 | 0.95 | CYP2C9 (0.51) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL9346492 | 0.95 | CYP2C9 (0.51) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL21456800 | 0.94 | DRD2 (0.51) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL5361264 | 0.93 | CYP2C9 (0.49) | CYP2C9MAPTALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 875 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4733949-A | LOW TEMPERATURE RESPONSE TIME | HITACHI, LTD. (JP) | 1988-03-29 | — | — | US | claimed |
| US-4469618-A | LOW VISCOSITY AT LOW TEMPERATURES | HITACHI, LTD. (JP) | 1984-09-04 | — | — | US | claimed |
| JP-60023402-A | — | — | None | — | — | JP | disclosed |
| JP-4103637-A | — | — | None | — | — | JP | disclosed |
| EP-4748905-A1 | LIQUID-CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026099217-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2026-05-15 | — | — | WO | disclosed |
| US-12618007-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2026-05-05 | — | — | US | disclosed |
| US-12595416-B2 | LC mixtures with negative delta epsilon containing CC-4-V1 and COB(S)-N-OM | MERCK PATENT GMBH (DE) | 2026-04-07 | — | — | US | disclosed |
| EP-4428214-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2026-03-04 | — | — | EP | disclosed |
| EP-4428213-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2026-03-04 | — | — | EP | disclosed |
| US-12552991-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2026-02-17 | — | — | US | disclosed |
| EP-0087056-A1 | Benzonitriles | MERCK PATENT GmbH (DE) | 1983-08-31 | — | — | EP | disclosed |
| US-4398803-A | Liquid crystal display element | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-08-16 | — | — | US | disclosed |
| EP-0030277-B1 | PARTIALLY HYDROGENATED OLIGO-1,4-PHENYLENES, DIELECTRICS CONTAINING THEM AND ELECTRO-OPTICAL INDICATING DEVICE | MERCK PATENT GmbH (DE) | 1983-07-27 | — | — | EP | disclosed |
| EP-0074608-A2 | Liquid crystal halogen compounds, process for their preparation, dielectric and dectrooptical display element containing them | MERCK PATENT GmbH (DE) | 1983-03-23 | — | — | EP | disclosed |
| EP-0069387-A2 | Liquid crystal display device | Hitachi, Ltd. (JP) | 1983-01-12 | — | — | EP | disclosed |
| US-4366080-A | Liquid crystal display element | TOKYO SHIBAURA DENKI KABUSHIKI KAISHA (JP) | 1982-12-28 | — | — | US | disclosed |
| US-4331552-A | Liquid crystalline, partially hydrogenated oligo-1,4-phenylenes and dielectrics and electro-optical display elements containing them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1982-05-25 | — | — | US | disclosed |
| EP-0037902-A1 | Liquid crystal display element | KABUSHIKI KAISHA TOSHIBA (JP) | 1981-10-21 | — | — | EP | disclosed |
| EP-0030277-A1 | Partially hydrogenated oligo-1,4-phenylenes, dielectrics containing them and electro-optical indicating device | MERCK PATENT GmbH (DE) | 1981-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552991-B2 | Liquid-crystalline medium | FES, VIM, INHA | CYP2C9 3372/4885MAPT 201/4885ALDH1A1 4721/4885 |
| US-12618007-B2 | Liquid-crystalline medium | SOST, NES, VIM | CYP2C9 4563/4885MAPT 176/4885ALDH1A1 4524/4885 |
| US-12595416-B2 | LC mixtures with negative delta epsilon containing CC-4-V1 and COB(S)-N-OM | CHRND, SCO2, ECH1 | CYP2C9 3389/4885MAPT 3202/4885ALDH1A1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.